Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2242 - OReO/ENGOT Ov-38: A Phase IIIb trial of olaparib maintenance retreatment in patients with epithelial ovarian cancer


09 Sep 2017


Poster display session


Cytotoxic Therapy;  Ovarian Cancer


Eric Pujade-Lauraine


Annals of Oncology (2017) 28 (suppl_5): v330-v354. 10.1093/annonc/mdx372


E. Pujade-Lauraine1, N. Colombo2, R. Glasspool3, B. Asselain4, T. Huzarski5, J. Korach6, F. Marme7, M.R. Mirza8, A. Redondo9, G. Scambia10, C. Blakeley11, A. Milner11, F. Selle12, I. Vergote13

Author affiliations

  • 1 ,, Université Paris Descartes, AP-HP and GINECO, , - Paris/FR
  • 2 ,, University of Milan-Bicocca, Istituto Europeo Oncologia and MANGO, Milan/IT
  • 3 ,, Beatson West of Scotland Cancer Centre and NCRI and SGCTG, Glasgow/GB
  • 4 ,, Institut Curie and GINECO, Paris/FR
  • 5 ,, Pomeranian Medical University, Szczecin/PL
  • 6 ,, Sheba Medical Centre, Tel Aviv University and ISGO, Tel Hashomer/IL
  • 7 ,, University Hospital Heidelberg and AGO, Heidelberg/DE
  • 8 ,, Rigshospitalet-Copenhagen University Hospital, Copenhagen/DK
  • 9 ,, Hospital Universitario La Paz and GEICO, Madrid/ES
  • 10 ,, Università Cattolica del Sacro Cuore di Roma, Rome/IT
  • 11 ,, AstraZeneca, Cambridge/GB
  • 12 ,, Hôpital Tenon and GINECO, Paris/FR
  • 13 ,, University Hospital Leuven and BGOG, Leuven/BE


Abstract 2242


A significant progression-free survival (PFS) improvement in all-comer patients (pts) with platinum-sensitive, relapsed (PSR), high-grade serous ovarian cancer supported the approval of olaparib (LynparzaTM) capsules as maintenance monotherapy (Ledermann et al NEJM 2012); these results were confirmed using the new olaparib tablet formulation in pts with a germline BRCA1/2 mutation (BRCAm) (Pujade-Lauraine et al SGO 2017). Pts with epithelial ovarian cancer (EOC) often retain platinum sensitivity despite progression on PARP inhibitor (PARPi) maintenance therapy. After relapse, it is unknown whether such pts could derive clinical benefit from olaparib retreatment. The OReO/ENGOT Ov-38 trial (NCT03106987; D0816C00014) will evaluate efficacy and safety of maintenance retreatment with olaparib tablets in all-comer pts with EOC.

Trial design

OReO/ENGOT Ov-38 is a randomized, placebo-controlled multicentre trial of olaparib maintenance retreatment in pts with non-mucinous EOC, and a complete or partial response to their most recent platinum-based chemotherapy. Eligibility requires prior receipt of maintenance PARPi therapy, or prior participation by pts in a study with a PARPi experimental arm. Randomization 2:1 to olaparib (300 mg twice daily tablets) or matching placebo will be split across two cohorts (approximately 416 pts): pts with a known BRCAm in cohort one; BRCA wild-type pts in cohort two. Pts with a known BRCAm (germline or somatic) must provide a tumour sample (archival or fresh) and a blood sample for post-analysis BRCA testing. Primary endpoint is investigator-assessed PFS (RECIST v1.1). Cohorts are independently powered at 80% to detect a PFS benefit (assuming a hazard ratio [olaparib:placebo] of 0.5 [cohort one] or 0.65 [cohort two]) at the two-sided 5% level. Table lists the secondary endpoints, including outcome measures for health-related quality of life. Enrolment began in Q2 2017.Table:

987TiP Secondary endpoints

TTP by GCIG criteria
PRO measures for HRQoL:
– Change from baseline in the TOI of the FACT-O
– Proportion of pts with an improved PRO score
– Best overall response (improved, no change, worsened, other)
– PRO deterioration-free survival

FACT-O, Functional Assessment of Cancer Therapy – Ovarian; GCIG, Gynecologic Cancer InterGroup; HRQoL, health-related quality of life; OS, overall survival; PRO, Patient Reported Outcome; TDT, time from randomization to study treatment discontinuation, or death; TFST, time from randomization to first subsequent treatment commencement, or death; TOI, Trial Outcome Index; TSST, time from randomization to second subsequent treatment commencement, or death; TTP, time to progression

Clinical trial identification


Legal entity responsible for the study

AstraZeneca and ENGOT




E. Pujade-Lauraine: Received advisory board membership and honoraria from AstraZeneca and Pfizer, and advisory board membership, honoraria and speakers\' bureau membership from Roche. N. Colombo: Received a grant from AstraZeneca, and personal fees from AstraZeneca, Roche, Pharmamar, Clovis, Pfizer and Tesaro. R. Glasspool: AstraZeneca: travel, registration, and accommodation for a non-compensated advisory board in June 2016, and for ASCO 2017. Advisory boards for Clovis and Tesaro (2016) and a speaker at a ROCHE meeting in March 2017. F. Marme: Received honoraria for Scientific advisory boards etc from: Roche, AstraZeneca, Novartis, Pfizer, PharmaMar, Eisai, Genmoic Health. M.R. Mirza: Board of Directors: Karyopharm., Metamark Genetics, Sera Prognostics Inc. Consultant/Advisory: Advaxis, AstraZeneca, Boehringer Ingelheim, Cerulean, Clovis, Genmab, Karyopharm, Novocure, Pfizer, Roche, Tesaro Study grants: AstraZeneca, Boehringer Ingelheim, Clovis, Pfizer, Roche, Tesaro. A. Redondo: AstraZeneca: Honoraria and travel expenses. C. Blakeley, A. Milner: Employed as a contractor for AstraZeneca, but does not own stock. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.